| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:839.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Cardiovascular Division (K.N.), Department of Medicine, Saga Medical School, Saga, Japan; Department of Internal Medicine and Therapeutics (M.F., M.H.), Osaka University Graduate School of Medicine, Osaka, Japan; Division of Cardiology (M.K.), National Cardiovascular Center, Osaka, Japan; and Cardiovascular Division (J.K.L.), Department of Medicine, Brigham & Womens Hospital and Harvard Medical School, Boston, Mass.
Correspondence and reprint requests to James K. Liao, MD, Brigham & Womens Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139 (e-mail jliao{at}rics.bwh.harvard.edu), or Koichi Node, MD, PhD, Cardiovascular Division, Department of Medicine, Saga University School of Medicine, 5-1-1 Nabeshima, Saga, 849-8501 Japan (e-mail nodekoi@post.saga-med.ac.jp).
Received November 12, 2001; de novo received April 24, 2003; accepted May 6, 2003.
Background Chronic heart failure is associated with inflammation and neurohormonal imbalance. The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, exert anti-inflammatory and vascular protective effects. We hypothesized that short-term statin therapy may have beneficial effects in patients with nonischemic heart failure.
Methods and Results Sixty-three patients with symptomatic, nonischemic, dilated cardiomyopathy were randomly divided into 2 groups. One group received simvastatin (n=24), and the other group received placebo (n=27). The initial dose of simvastatin was 5 mg/d, which was increased to 10 mg/d after 4 weeks. After 14 weeks, patients receiving simvastatin exhibited a modest reduction in serum cholesterol level compared with patients receiving placebo (130±13 versus 148±18, P<0.05). Patients treated with simvastatin had a lower New York Heart Association functional class compared with patients receiving placebo (2.04±0.06 versus 2.32±0.05, P<0.01). This corresponded to improved left ventricular ejection fraction in the simvastatin group (34±3 to 41±4%, P<0.05) but not in the placebo group. Furthermore, plasma concentrations of tumor necrosis factor-
, interleukin-6, and brain natriuretic peptide were significantly lower in the simvastatin group compared with the placebo group.
Conclusions Short-term statin therapy improves cardiac function, neurohormonal imbalance, and symptoms associated with idiopathic dilated cardiomyopathy. These findings suggest that statins may have therapeutic benefits in patients with heart failure irrespective of serum cholesterol levels or atherosclerotic heart disease.
Key Words: heart failure statins cholesterol endothelium inflammation
This article has been cited by other articles:
![]() |
Z. L. S. Brookes, C. C. McGown, and C. S. Reilly Statins for all: the new premed? Br. J. Anaesth., July 1, 2009; 103(1): 99 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bolli and B. Dawn The Cornucopia of "Pleiotropic" Actions of Statins: Myogenesis As a New Mechanism for Statin-Induced Benefits? Circ. Res., January 30, 2009; 104(2): 144 - 146. [Full Text] [PDF] |
||||
![]() |
G. Suzuki, V. Iyer, T. Cimato, and J. M. Canty Jr Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133+ and cKit+ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle Circ. Res., January 30, 2009; 104(2): 255 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Circulation, September 16, 2008; 118(12): 1285 - 1293. [Full Text] [PDF] |
||||
![]() |
R. C Parish and J. D Evans Inflammation in Chronic Heart Failure Ann. Pharmacother., July 1, 2008; 42(7): 1002 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Young, C. H. Strey, P. M. George, C. M. Florkowski, C. W. Sies, C. M. Frampton, and R. S. Scott Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure Eur J Heart Fail, May 1, 2008; 10(5): 463 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency Circ. Res., January 4, 2008; 102(1): 68 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF] |
||||
![]() |
V. Zaca, S. Rastogi, M. Imai, M. Wang, V. G. Sharov, A. Jiang, S. Goldstein, and H. N. Sabbah Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure J. Am. Coll. Cardiol., August 7, 2007; 50(6): 551 - 557. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure Cardiovasc Res, April 1, 2007; 74(1): 75 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ray, C. M. Norris, J. A. Udell, R. T. Tsuyuki, F. A. McAlister, M. L. Knudtson, and W. A. Ghali Lipid-Lowering Therapy and Outcomes in Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 27 - 35. [Abstract] [PDF] |
||||
![]() |
K. K. Khush, D. D. Waters, V. Bittner, P. C. Deedwania, J. J.P. Kastelein, S. J. Lewis, and N. K. Wenger Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study Circulation, February 6, 2007; 115(5): 576 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hauck, C. Harms, D. Grothe, J. An, K. Gertz, G. Kronenberg, R. Dietz, M. Endres, and R. von Harsdorf Critical Role for FoxO3a-Dependent Regulation of p21CIP1/WAF1 in Response to Statin Signaling in Cardiac Myocytes Circ. Res., January 5, 2007; 100(1): 50 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
A F Leite-Moreira and P Castro-Chaves Heart failure: statins for all? Heart, November 1, 2006; 92(11): 1537 - 1538. [Full Text] [PDF] |
||||
![]() |
C H Strey, J M Young, J H Lainchbury, C M Frampton, M G Nicholls, A M Richards, and R S Scott Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure Heart, November 1, 2006; 92(11): 1603 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cavusoglu, C. Ruwende, V. Chopra, S. Yanamadala, C. Eng, L. T. Clark, D. J. Pinsky, and J. D. Marmur Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain Eur. Heart J., October 1, 2006; 27(19): 2300 - 2309. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Goldberger, H. Subacius, A. Schaechter, A. Howard, R. Berger, A. Shalaby, J. Levine, A. H. Kadish, and for the DEFINITE Investigators Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1228 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Collard, S. C. Body, S. K. Shernan, S. Wang, D. T. Mangano, and Multicenter Study of Perioperative Ischemia (MCSPI Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 392 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen Statins in the treatment of chronic heart failure: Biological and clinical considerations Cardiovasc Res, August 1, 2006; 71(3): 443 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Scirica, D. A. Morrow, C. P. Cannon, K. K. Ray, M. S. Sabatine, P. Jarolim, A. Shui, C. H. McCabe, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2326 - 2331. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Christ, T. Klima, W. Grimm, H.-H. Mueller, and B. Maisch Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy Eur. Heart J., March 2, 2006; 27(6): 691 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Foody, R. Shah, D. Galusha, F. A. Masoudi, E. P. Havranek, and H. M. Krumholz Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure Circulation, February 28, 2006; 113(8): 1086 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ramasubbu and D. L. Mann The Emerging Role of Statins in the Treatment of Heart Failure J. Am. Coll. Cardiol., January 17, 2006; 47(2): 342 - 344. [Full Text] [PDF] |
||||
![]() |
B. E. Bleske, J. M. Nicklas, R. L. Bard, R. D. Brook, P. A. Gurbel, K. P. Bliden, S. Rajagopalan, and B. Pitt Neutral Effect on Markers of Heart Failure, Inflammation, Endothelial Activation and Function, and Vagal Tone After High-Dose HMG-CoA Reductase Inhibition in Non-Diabetic Patients With Non-Ischemic Cardiomyopathy and Average Low-Density Lipoprotein Level J. Am. Coll. Cardiol., January 17, 2006; 47(2): 338 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sola, M. Q.S. Mir, S. Lerakis, N. Tandon, and B. V. Khan Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure J. Am. Coll. Cardiol., January 17, 2006; 47(2): 332 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D.M. Engelmann and J. H. Svendsen Inflammation in the genesis and perpetuation of atrial fibrillation Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kjekshus, P. Dunselman, M. Blideskog, C. Eskilson, A. Hjalmarson, J. V. McMurray, F. Waagstein, H. Wedel, P. Wessman, J. Wikstrand, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics Eur J Heart Fail, October 1, 2005; 7(6): 1059 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure: Roles of Angiotensin II Type 1 Receptors and NAD(P)H Oxidase Circulation, September 20, 2005; 112(12): 1763 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yaoita, K. Yoshinari, K. Maehara, M. Sando, K. Watanabe, and Y. Maruyama Different Effects of a High-Cholesterol Diet on Ischemic Cardiac Dysfunction and Remodeling Induced by Coronary Stenosis and Coronary Occlusion J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2078 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
A D Gavin and A D Struthers Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure Heart, June 1, 2005; 91(6): 749 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, C. Manes, D. Fischer, K. de Groot, D. Fliser, et al. Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans Circulation, May 10, 2005; 111(18): 2356 - 2363. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. O'Neil-Callahan, G. Katsimaglis, M. R. Tepper, J. Ryan, C. Mosby, J. P.A. Ioannidis, and P. G. Danias Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk Reduction in Surgery (StaRRS) study J. Am. Coll. Cardiol., February 1, 2005; 45(3): 336 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ray, Y. Gong, K. Sykora, and J. V. Tu Statin Use and Survival Outcomes in Elderly Patients With Heart Failure Arch Intern Med, January 10, 2005; 165(1): 62 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Azuma, J.-i. Suzuki, M. Ogawa, H. Futamatsu, N. Koga, Y. Onai, H. Kosuge, and M. Isobe HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation Cardiovasc Res, December 1, 2004; 64(3): 412 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Porter, N. A. Turner, D. J. O'Regan, and S. G. Ball Tumor necrosis factor {alpha} induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin Cardiovasc Res, December 1, 2004; 64(3): 507 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Massion, C. Dessy, F. Desjardins, M. Pelat, X. Havaux, C. Belge, P. Moulin, Y. Guiot, O. Feron, S. Janssens, et al. Cardiomyocyte-Restricted Overexpression of Endothelial Nitric Oxide Synthase (NOS3) Attenuates {beta}-Adrenergic Stimulation and Reinforces Vagal Inhibition of Cardiac Contraction Circulation, October 26, 2004; 110(17): 2666 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, N. Engberding, F. H. Bahlmann, A. Schaefer, A. Wiencke, A. Heineke, S. Spiekermann, D. Hilfiker-Kleiner, C. Templin, D. Kotlarz, et al. Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase Circulation, October 5, 2004; 110(14): 1933 - 1939. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Pan, T. Pintar, J. Anton, V.-V. Lee, W. K. Vaughn, and C. D. Collard Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery Circulation, September 14, 2004; 110(11_suppl_1): II-45 - II-49. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ito, T. Adachi, D. R. Pimentel, Y. Ido, and W. S. Colucci Statins Inhibit {beta}-Adrenergic Receptor-Stimulated Apoptosis in Adult Rat Ventricular Myocytes via a Rac1-Dependent Mechanism Circulation, July 27, 2004; 110(4): 412 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Tsirka, K. Trinkaus, S.-C. Chen, S. E. Lipshultz, J. A. Towbin, S. D. Colan, V. Exil, A. W. Strauss, and C. E. Canter Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation J. Am. Coll. Cardiol., July 21, 2004; 44(2): 391 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Sacks High-Intensity Statin Treatment for Coronary Heart Disease JAMA, March 3, 2004; 291(9): 1132 - 1134. [Full Text] [PDF] |
||||
![]() |
F.M Sacks Do statins play a role in the early management of the acute coronary syndrome? Eur. Heart J. Suppl., March 1, 2004; 6(suppl_A): A32 - A36. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. van der Harst, A. A. Voors, D. J. van Veldhuisen, J. K. Liao, K. Node, M. Fujita, M. Hori, and M. Kitakaze Short-Term Statin Therapy and Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy * Response Circulation, February 10, 2004; 109 (5): e34 - e34. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |